Oxaliplatin-based regimens induce a potential risk of hypersensitivity reaction (HSR), with incidence varying from 10% to 25% and lack of clearly identified risk factors. The present study aimed to assess inci...
Authors:
Marie Parel, Florence Ranchon, Audrey Nosbaum, Benoit You, Nicolas Vantard, Vérane Schwiertz, Chloé Gourc, Noémie Gauthier, Marie-Gabrielle Guedat, Sophie He, Eléna Kiouris, Céline Alloux, Thierry Vial, Véronique Trillet-Lenoir, Gilles Freyer, Frédéric Berard…
Citation:
BMC Pharmacology and Toxicology
2014
15:1
Content type: Research article
Published on: 13 January 2014